ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 121 citations in OpenAlex.
- Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
- miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells.Journal of cellular and molecular medicine · 2026Article
- Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo.Cancer chemotherapy and pharmacology · 2026Article
- Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.Journal of hematology & oncology · 2026Review
- Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics.Journal of advanced research · 2026Review
- Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based onInternational journal of molecular sciences · 2026Article
- Targeting Aurora A Kinase Enhance the CDK4/6 Inhibitor Sensitivity in HR+/HER2- Breast Cancer.Oncology research · 2026Article
- Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4/6 Inhibitors.Pharmacological research · 2025Review
- Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR + /HER2- metastatic breast cancer patients.Journal of translational medicine · 2025Article
- Review
- Targeting CDK4/6 in breast cancer.Experimental & molecular medicine · 2025Review
- The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.Cancer research communications · 2025Article
- TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer.Cancer letters · 2025Article
- CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response.Cell death discovery · 2024Article
- AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.bioRxiv : the preprint server for biology · 2024Article
- CDK4/6 Inhibition With Lerociclib is a Potential Therapeutic Strategy for the Treatment of Pediatric Sarcomas.Journal of pediatric surgery · 2024Article
- Article
- Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review.Breast cancer (Dove Medical Press) · 2024Review
- TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells.International journal of molecular sciences · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Renée de LeeuwDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Christopher McNairDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Matthew J SchiewerDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Neermala Poudel NeupaneDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Lucas J BrandDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Michael A AugelloDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Zhen LiRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Larry C ChengRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.ORCID 0000-0002-6922-6433
Akihiro YoshidaDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
Sean M CourtneyCenter for Genomic Medicine Bioinformatics, Medical University of South Carolina (MUSC), Charleston, South Carolina.
E Starr HazardCenter for Genomic Medicine Bioinformatics, Medical University of South Carolina (MUSC), Charleston, South Carolina.
Gary HardimanCenter for Genomic Medicine Bioinformatics, Medical University of South Carolina (MUSC), Charleston, South Carolina.
Maha H HussainDivision of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois.
J Alan DiehlDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
Justin M DrakeRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Wm Kevin KellyDepartment of Medical Oncology, Urology and Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Karen E KnudsenDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania. karen.knudsen@jefferson.edu.
Thomas Jefferson University · USMedical University of South Carolina · USRutgers, The State University of New Jersey · USMUSC Hollings Cancer Center · USRobert H. Lurie Comprehensive Cancer Center of Northwestern University
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8MUMDNJ TRAINING GRANT IN BIOTECHNOLOGYT32GM008339 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI YARMUSH, MARTIN L · 1989 to 2019
$6.1MNuclear Accumulation of D-type Cyclins and OncogenesisR01CA093237 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DIEHL, JOHN ALAN · 2001 to 2022
$5.9MRB Function in Prostate Cancer ProgressionR01CA176401 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, KAREN E · 2014 to 2018
$2.2MTargeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate CancerR01CA217329 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KELLY, WILLIAM K., MCNAIR, CHRISTOPHER MICHAEL · 2017 to 2021
$1.8MSWI/SNF dysregulation in development and diseaseR01CA159945 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, KAREN E · 2012 to 2016
$1.6MNCI NIH HHS P30 CA056036NCI NIH HHS R01 CA093237NCI NIH HHS R01 CA159945NCI NIH HHS R01 CA176401NCI NIH HHS R01 CA217329NIGMS NIH HHS T32 GM008339
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drug Resistance, NeoplasmDual Specificity Phosphatase 1HumansMAP Kinase Kinase 1MAP Kinase Kinase KinasesNeoplasm InvasivenessNeoplasmsPhosphorylationPiperazinesPyridinesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Dual Specificity Phosphatase 1MAP Kinase Kinase 1MAP Kinase Kinase KinasespalbociclibPiperazinesPyridinesRetinoblastoma Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.